Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older at average risk. This test offers a convenient alternative for those who decline or do not complete stool-based or visual screening methods, aiming to increase screening rates among the 60 million Americans due for screening. SimpleScreen CRC detects cancer signals via circulating cell-free DNA and showed 81.1% sensitivity in clinical trials. Covered by Medicare with no out-of-pocket costs for eligible patients, Abbott also provides patient support services to help complete the screening process, with follow-up colonoscopy recommended for positive results.
Abbott Laboratories (ABT) shares are trading at USD 101.00 as of Sep 30, 2026 19:11 WIB, close to their 52-week low of USD 82.57 but well below the 52-week high of USD 134.59. Despite a modest 1-day gain of 0.06%, the stock sees more selling pressure on Pluang with 79% of orders to sell versus 21% to buy. The dividend yield stands at 2.5%, and typical investors hold the stock for about 96 days, reflecting cautious sentiment around the health sector name amid its new product launches.
Abbott announced results from the Beta-CORRECT study showing its Oncodetect test, using whole-genome sequencing, improves detection of molecular residual disease (MRD) in colorectal cancer patients after surgery. The test showed a 30% higher sensitiv...
Abbott Laboratories announced plans to spin off its Nutrition division to concentrate on higher-growth areas like diagnostics, medical devices, and pharmaceuticals. The company reported a 14.5% increase in Q3 revenue to $13.01 billion, driven mainly ...
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
